Epilepsy is a neurologic disorder consisting of recurrent spontaneous seizures. Antiepileptic drugs administration is the most commonly used therapeutic strategy in the management of epilepsy. However, 20-30% of epilepsy patients have seizure episodes that are not controlled by these medicines (drug-resistant epilepsy). The management of drug-resistant epilepsy, especially in the children, is challenging and can cause economic and social problems, and lower the patients' quality of life, cognition, and mood. Several therapeutic approaches for drug-resistant epilepsy are available including surgical methods, neurostimulation treatments, and diet therapies which lead to diminishing the epileptic seizures. An increasing number of novel and potential therapeutic approaches such as gene therapy, gene editing, cell therapy, exosome therapy, and molecular network targeting have also been explored. The present study is aimed to review these current and emerging therapeutic approaches for drug-resistant epilepsy.
Introduction
Epilepsy is a neurologic disease consisting of recurrent spontaneous seizures arising from brain excitation and inhibition imbalance [1] . It may have life-threatening episodes in children [2, 3] . Clinical manifestation of epilepsy is recognized by epileptic seizure (ES) which can be defined as a rhythmic firing of neuron population causing behavioral changes [4, 5] . The incidence rate of epilepsy is characterized as a U-shaped diagram with a higher incidence in neonatal and young patients, and in elderly patients over 75 years old as well [6] . Different therapeutic approaches are available for epilepsy which anti-epileptic drugs (AED) are in the first line of treatment. Despite many available anti-epilepsy drugs, 20-30% of epilepsy patients have seizure episodes that are not controlled by these medicines [drug-resistant epilepsy (DRE)] [7, 8] causing the increased risk of injuries, lower socioeconomic status, quality of life, cognition and mood [9] [10] [11] . Furthermore, behavioral disorders including depression and anxiety in these patients and their family are more common compared to the general population [4, 10, 12, 13] . Other therapeutic methods dependent to the localization of seizure onset, seizure type, age and disease condition are also available including surgery, neurostimulation treatment, diet therapy, and some emerging treatments such as the gene, cell, and exosome therapies [14, 15] . Therefore, the aim of this review is to introduce general information about the several current and emerging therapeutic approaches for DRE in children and explaining the probable involved biochemical mechanisms of them.
Surgery
Epilepsy surgery can be considered as an effective procedure for ES elimination or reduction by excising the brain epileptic zone or restrict the spread of seizure activity [16, 17] . This method can be useful in DRE children, especially in their early life [18] . The surgery is aimed to improve 1 3 ES control without causing any loss of normal brain function. Overall, when appropriate, it is safe, highly effective, underutilized, and better than ongoing medical therapy in the management of epilepsy [16, 17, 19, 20] .
The evaluation of children that are candidates for the surgery includes three parts. The first level is to confirm whether the patient does truly have epileptic seizures. The second task, it is essential to confirm the intractable nature of the disease in the child. The last part is to localize the epileptic zone [21, 22] .
Types of the surgery
The type of performed surgery depends on the type and source of the ES in the brain. Based on the aim of the surgery, epilepsy surgery can be divided into two types: curative and palliative procedures (Fig. 1) [23] .
Curative procedure
Curative surgery is usually achieved when the seizure source in the brain can be located by the tests. This type of procedure aims to remove all area of the brain causing seizures (seizure focus) without leading loss of brain function. Lobectomy, cortical excision, or hemispherectomy are examples of curative surgeries [23] .
Temporal lobectomy It is the most common procedure in adult patients with temporal lobe epilepsy. In this surgery, a part of the anterior temporal lobe along with the amygdala and hippocampus is removed. It leads to a significant reduction or complete seizure control (70-80%). As the disadvantages, language and memory can be affected by this surgery on the dominant hemisphere [16, 23, 24] .
Cortical excision It can be considered as the second most common type of epilepsy surgery in adults and is probably the most common surgery in children. The outer layer (cortex) of the brain at the seizure focus area is removed in this procedure. About 40-50% of patients have been shown to better seizure control by this procedure [16, 23] .
Hemispherectomy Hemispherectomy is another surgical approach in the treatment of DRE. Initially, an entire hemisphere was resected in this procedure which was frequently done in the 1950s and 1960s. It was associated with several complications including late-onset hydrocephalus, superficial cerebral hemosiderosis, and death. Therefore, it has recently been replaced with "hemispherotomy" which mostly relies on disconnection, and minimizes the brain removal. In this less invasive procedure, the epileptogenic cortex of one hemisphere from the contralateral hemisphere and deeper brain structures is disconnected or epileptogenic cortex is only removed. These procedures are associated with comparable seizure control rates (about 80%) but a lower incidence of the complications. This type of surgery is primarily used in children. The reason for the uncertainty to apply it in adults is mostly related to potentially irreversible brain damage that does not have the same plasticity as in the pediatric population [25, 26] .
Palliative procedures
A palliative procedure is usually performed when the ES source cannot be located or overlaps critical regions of the brain such as movement, speech, or vision. The aim of this type of procedure is reducing the frequency or severity of the seizures. The palliative producers often do not provide complete remission for the patients but they are still helpful in patients not having the chance of complete seizure control. Corpus callosotomy and multiple subpial transections are examples of palliative procedure [16, 23, 27] .
Corpus callosotomy
In this surgery, the spread of ESs from one side of the brain to the other is prevented by cutting of the anterior two-thirds of the nerve fibers across the corpus callosum. If no obvious improvement occurs, a second surgery may be executed to cut the remaining posterior onethird of the corpus callosum. As of disadvantages, the disconnection syndrome may be experienced by some patients after a complete callosotomy. They have right-left confusion with motor problems, apathy, or mutism [16, 27] .
Multiple subpial transections
This procedure is usually performed when the seizure source is located in a vital area of the brain that cannot be removed. In this technique, small vertical incisions are created in the epileptogenic cortex interrupting the horizontal cortical connections to interfere with the spread of ES impulses. It can be performed alone or in combination with a lobectomy [23, 27] .
Vagus nerve stimulation
Vagus nerve stimulation (VNS) is an electrical stimulation therapy that can be effective in treating DRE patients who are not the candidates for curative brain surgery. It includes periodic electrical stimulation supplied by a programmable pulse generator to deliver to the vagus. This device is similar to a heart pacemaker that produces intermittent electrical signals that travel along the vagus nerve to the brain to prevent seizures. A wire with bipolar leads is wrapped around the vagus nerve in the neck which is connected to the stimulating device which can be implanted under the skin of the patient anterior chest wall. It has been shown that 30-40% of patients achieved a 40-50% seizure frequency reduction by VNS procedure [28] [29] [30] . This method has several advantages. Its efficacy is retained during prolonged stimulation, and the control of ESs improves with time. Any cognitive impairment or adverse drug interactions are not associated. Unlike the main surgical methods, VNS is a potentially reversible form of therapeutic approach [31] . Although VNS is a safe and well-tolerated approach, it may have some adverse side effects which can be related with both the surgical procedure part and the electrical stimulation itself. Infection is the most critical implantation-related side effect. Bradycardia, asystole, and vocal cord paresis have also been detected during implantation. The most prevalent stimulation-related side effects include cough, voice hoarseness, headache, paresthesia, pharyngitis, dyspnea, and pain. These side effects usually tend to diminish with time but sometimes it may require a decrease in stimulation strength or device deactivation [28] [29] [30] . Trigeminal nerve stimulation and deep-brain stimulation are other types of electrical stimulation that can be achieved alternatively in DRE management [32] . Recently, a noninvasive VNS (nVNS) system has been developed that omits the need for surgical implantation and its side effects. This novel system of VNS permits patients to apply stimulation when required. It is more available and its safety and tolerability have been modified that may lead to widening the range of uses. However, it has not yet been used in children, and further evaluation and studies are needed [29] .
Ketogenic diet
According to the lack of access, high cost, and the complications of surgical procedures, the use of an easy therapeutic approach such as regimen therapy can be necessary for the management of DRE. The ketogenic diet (KD), introduced initially by Wilder in 1921 [33] , has long been used as an alternative therapeutic approach for DRE and is considerably effective in reducing several seizure types, especially in surgery unachievable cases [34, 35] . Using of KD has also been expanded to the other diseases including inherent metabolic diseases, autism, and glioblastoma [36] . It is a high fat, low carbohydrate, and sufficient protein, vitamin, and mineral diet which can simulate the metabolic state of fasting while retaining a normal amount of calories [34, 37] . It means that fat supplies the most of the daily energy intake and the remaining will be derived from carbohydrates and proteins [38] . Various types of KD have been implicated in DRE treatment that include classic KD, medium-chain triglyceride diet, modified Atkins diet, and low glycemic index treatment. Despite some differences in their composition, all the diets have nearly similar efficacy and the majority of patients have been shown to achieve at least 50% reduction in their seizure activity after the KD therapy [39] [40] [41] . Although the mechanisms involved in improving seizure have not yet been completely understood [34] , it may affect the intermediate metabolism which impresses the main excitatory and inhibitory systems in the brain [39] .
The use of LGIT in treating epilepsy was initially reported in 2005.
Antioxidant therapy
Over the past decade, there were several pieces of evidence for the role of oxidative stress in epilepsy pathogenesis [42] . The most important effect of free radicals is lipid peroxidation, which causes cell membrane disruption, leading to their destruction [43] . High oxygen utilization, high polyunsaturated fatty acids concentrations, rich in iron (which can catalyze hydroxyl radical formation), and less antioxidant capacity than other tissues, make the brain prone to lipid peroxidation and oxidative damage [43, 44] . Recurrent seizures can increase the content of ROS generation in the brain. On the other hand, increased oxidative stress in the brain can induce seizure activity, thereby a vicious cycle is created [43] .
The biological effects of free radicals can be controlled by a variety of antioxidants including vitamins A, vitamin C, vitamin E, and glutathione, in addition to antioxidant enzymes such as glutathione reductase, glutathione peroxidase, superoxide dismutase, and catalase. Previous studies suggest that therapeutic intervention with antioxidant components including melatonin, lipoic acid, vitamin C, vitamin E, polyphenols (such as curcumin), and N-acetylcysteine (a glutathione precursor) may be a beneficial strategy for diminishing neurodegeneration in susceptible neuronal targets of DRE [44] . Therefore, antioxidant therapy aimed at decreasing oxidative stress can be helpful in alleviating the seizures in DRE patients [43] .
Novel therapeutic approaches

Gene therapy
The use of novel therapeutic approaches in the management of epilepsy is steadily progressing [45] . Neurological disorders are sometimes caused by inherited or acquired genetic changes that lead to abnormal nervous system development, neurodegeneration, or impaired neuronal function [46] . About 30% of the epilepsies have been thought to have a genetic origin [47] .
Gene therapy, as an emerging and novel therapeutic approach has curative potentials of the most common neurological disorders including DRE [46] . It had formerly defined as a method to replace the defective copy of a gene with a normal copy which acts correctly in the cells [48] .
There are various methods to transfer and express a gene in a particular region of the brain that include cell transplantation, liposomes, non-viral and viral vector delivery, (adenovirus, adeno-associated virus, herpes simplex virus, lentivirus, and retrovirus) [15, 48] .
Gene therapy for DRE treatment aims to induce the local release of anticonvulsant or antiepileptogenic properties to counterbalance between excitation and inhibition in the brain [14] . It offers the possibility of targeting therapeutic genes expressing in the seizure generating area without needing tissue ablation [49] . Altering the expression of some therapeutic genes such as GABA A receptor [50] , galanin [51] , NPY [52] , glial cell-line-derived neurotrophic factor [53] , brain-derived neurotrophic factor [54] , and fibroblast growth factor-2 have been also associated with successful outcomes [55] .
These results are very promising; however, it is important to note that only infrequent types of epilepsy are caused by a single mutant gene; while they are commonly caused by inheritance of two or more susceptibility genes that usually influence a large part of the brain. Therefore, an extensive gene transfer is needed; however, the presently available gene therapies provide only local effects [47] . Improvement in the gene therapy-treating epilepsy can be possible through progress in understanding the disease mechanisms, designing suitable gene vectors, selecting suitable genes, and choosing the right delivery methods [46] . Taken together, gene therapy can be considered as a therapeutic approach in the management of epilepsy; but further studies are needed to verify the safety and efficacy of this method in human.
Gene editing
Gene therapy is a more challenging and complicated process than the simple concept of gene replacement. Techniques for transferring of exogenous genes into the desired sequence of target cells have been remarkably improved [56] . Clustered regularly interspaced short palindromic repeats (CRISPR) are types of nucleic acid sequences that function in harmony with CRISPR-associated (Cas) proteins to provide immunity in bacteria and archaea against foreign invasion of nucleotides such as viruses, plasmid, and phages [57] . Type II of this adaptive bacterial immune system has been engineered in recent years and provides a novel and powerful technique for accurate manipulating of genomic sequences [58] . It has two main components: Cas9 protein which acts as an endonuclease and cuts a targeted DNA. A guide-RNA (gRNA) guides the Cas9 to a specific genome location. This causes a precise double-strand break (DSB) of the DNA in the desired genome region [59] . The created DSB can trigger genome editing via two separate mechanisms. Non-homologous end joining (NHEJ) is a process which makes errorprone insertions or deletions of nucleotides to repair DSB without any homologous template DNA. Homology directed repair (HDR) is the second process in which the DSB can be repaired accurately in the presence of a synthetic DNA template. Any desired base-pair changes (gene editing) in the targeted genome sequences can be created by HDR [57] .
CRISPR-Cas9 system has recently attracted increasing attention for therapeutic applications [56, 57] . This system has presented a novel approach in repairing gene defects for treating various types of disorders including neurological diseases. It has been successfully used for therapeutic purposes in several in vitro and in vivo studies on neurological disorders associated with gene defects [59] [60] [61] [62] . Due to its potential in targeted gene editing and repairing of genetic mutations, CRISPR-Cas9 can also be considered for applying as a possible therapeutic approach in treating DRE with genetic origins [59] . Although it is the most powerful and useful technique for the multiplexed genome manipulating, there are still some challenges regarding efficiency and accuracy concerns, and further studies are needed to verify its safety before clinical applications.
Cell therapy
Repair of injured tissues is essential for any individual life and survival. It depends on the replacement of dead cells by new identical cells which could restore the original structure and function of the damaged tissue. The mammalian CNS has a weak capability for cell replacement and repairing. Cell transplantation can be considered as a potential treatment to overcome the intrinsic inability of the nervous tissue self-repairing [63] . The clinical possibility of stem cell therapy has been revealed in various neurological diseases including multiple sclerosis, Parkinson's disease, and stroke [45, 63] . It has also been progressively considered as a potential therapeutic alternative for epilepsy [45] .
Several studies with the aim of epilepsy treating have applied various cell types such as neural stem cells, mesenchymal stem cells, hippocampal precursor cells, GABAergic precursor cells, and bone marrow-derived mononuclear cells. They all aim to diminish seizure severity and frequency in the brain through different mechanisms of action [45] . Although the results are encouraging, to use cell therapy in clinical application, additional and vigorous studies are necessary to test safety and efficacy of this approach [45] .
Exosome therapy
The exosome is a kind of extracellular vesicles which have initially been recognized in the 1980s [64, 65] . Exosomes are characterized by homogeneous shaped nano (40-100 nm) membranous vesicles with a density of 1.13-1.19 g/cm2. They can be secreted by several body cell types and have been detected in the various biological fluids including blood, urine, saliva, CSF, breast milk, amniotic fluid, malignant ascites, bronchoalveolar fluid, and synovial fluid [66, 67] . Depending on their source cells, exosomes can contain a variety of lipids, proteins, and genetic elements such as DNA, non-coding RNAs, mRNAs, and microRNAs. These agents which are also known as "cargo" can be delivered to the surrounding cells or transferred to other distal cells and alter the recipient cell function. Therefore, exosomes can be considered as a novel form of intercellular communication [66] .
Interestingly, it has been shown that many cells of the nervous system such as neurons, microglia, astrocytes, oligodendrocytes, and neural stem cells can release exosomes. Thus, exosomes may have a role in the function, development, and pathologies of the nervous system [66, 68] .
Emerging pieces of evidence have suggested that exosomes can be used to rescue neuronal pathologies and alterations. It has been revealed that these vesicles have crucial roles in the regeneration process and repair of the nervous system. Their simple structure, low immunogenicity, and ability to cross the blood-brain barrier (BBB) have made a great opportunity to engineer and apply them as vehicles for delivering microRNAs, drugs, proteins, and other active agents to the brain [66] [67] [68] . MicroRNAs have been known as master regulators of gene expression. In the nervous system, they can alter the regulation of various proteins which associate with several neuronal processes and actions. They have been shown to can regulate essential genes involved in seizure susceptibility [68] . Therefore, exosomes contained the agents which have anti-seizure activity can be potentially applied to manage and treat epilepsy. However, more studies are needed to address their use in clinical trials [66] [67] [68] [69] .
Molecular networks as potential targets for novel epilepsy therapies
In recent years, the improvement in the epilepsy therapeutic approaches has mostly been relevant to target the alternative pathways in the brain beyond modulating the excitatory-inhibitory imbalance. Molecular networks can be considered as novel alternative targets which are often disrupted following seizures and in chronic epilepsy [1] .
Recent clinical and animal model studies have been demonstrated that disruption in "mammalian target of rapamycin" (mTOR) signaling in the brain might be associated with epilepsy [70, 71] . In addition, pharmacological inhibition of mTOR with rapamycin or everolimus (an analog of rapamycin) has found to be effective in reducing seizure frequency and neuronal death [1, 72, 73] .
The Wnt/β-catenin pathway is another signaling pathway which has recently got attention in being associated with epilepsy. It has been revealed that disruption in this pathway could be associated with both chronic and acute phases of epilepsy. This signaling pathway has been shown to associate with many processes such as neurogenesis and neuronal death in the brain [1] . It can induce hippocampal neurogenesis during seizures, which can provide new approaches for epilepsy therapy [74] . Therefore, using approved drugs or other agents to induce Wnt/β-cateninsignaling cascade or antagonize its inhibitors may alleviate the seizures in epilepsy. However, further studies are necessary to evaluate their safety and apply them in clinical trials. Overall, the molecular networks such as mTOR and Wnt/β-catenin pathways could be considered as favorable anti-epileptogenic targets for future epilepsy therapies [1] .
Conclusion
Antiepileptic drug administration is the most commonly used strategy in the management of epilepsy. However, the most important part of its economic and social cost is due to DRE patients with seizure episodes that are not controlled by standard medical therapy [75] . Several therapeutic approaches for DRE are available including surgical methods, neurostimulation treatments, and diet therapies which lead to diminishing the epileptic seizures through different mechanisms. The increasing numbers of novel therapeutic approaches such as gene therapy, gene editing (CRSPRCas9), cell therapy, exosome therapy, and molecular network targeting have also been explored. Although many encouraging results from several studies have been achieved; these emerging methods are currently considered as the potential therapeutic approaches in the management of DRE, and, therefore, more intensive and rigorous studies are needed to test their safety and efficacy and apply them in clinical trials.
